Ascendis Pharma (ASND) EVP reports initial RSU holdings in Form 3

Rhea-AI Filing Summary

Ascendis Pharma A/S executive Shu Aimee, EVP & Chief Medical Officer, filed an initial Form 3 reporting equity holdings in the company. The filing lists direct holdings of restricted stock units (RSUs) convertible into 6,532, 3,197, and 9,552 ordinary shares, plus no directly held ordinary shares. Each RSU represents a right to receive one American Depositary Share, and each ADS represents one ordinary share. The RSUs vest beginning on March 1, 2027, with some grants vesting fully on that date and others in two or three equal annual installments starting then.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Shu Aimee

Role EVP & Chief Medical Officer

Type	Security	Shares	Price	Value
holding	Restricted Stock Units	--	--	--
holding	Restricted Stock Units	--	--	--
holding	Restricted Stock Units	--	--	--
holding	Ordinary Shares	--	--	--

Holdings After Transaction: Restricted Stock Units — 6,532 shares (Direct); Ordinary Shares — 0 shares (Direct)

Footnotes (1)

1. Includes American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share. The restricted stock units vest on March 1, 2027 and have no expiration date. Each restricted stock unit represents a contingent right to receive one ADS. The restricted stock units vest in two equal annual installments beginning on March 1, 2027. The restricted stock units vest in three equal annual installments beginning on March 1, 2027.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Shu Aimee

(Last) (First) (Middle)

C/O ASCENDIS PHARMA A/S

TUBORG BOULEVARD 12

(Street)

HELLERUP DK-2900

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Ascendis Pharma A/S [ ASND ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Chief Medical Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares(1)	0	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(2)	(2)	Ordinary Shares	6,532	(3)	D
Restricted Stock Units	(4)	(4)	Ordinary Shares	3,197	(3)	D
Restricted Stock Units	(5)	(5)	Ordinary Shares	9,552	(3)	D

Explanation of Responses:

1. Includes American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share.

2. The restricted stock units vest on March 1, 2027 and have no expiration date.

3. Each restricted stock unit represents a contingent right to receive one ADS.

4. The restricted stock units vest in two equal annual installments beginning on March 1, 2027.

5. The restricted stock units vest in three equal annual installments beginning on March 1, 2027.

	/s/ Michael Wolff Jensen as attorney-in-fact for Aimee Shu	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Shu Aimee’s Form 3 filing for Ascendis Pharma (ASND) report?

The Form 3 reports Shu Aimee’s initial equity holdings in Ascendis Pharma. It details several grants of restricted stock units tied to ordinary shares and American Depositary Shares, along with vesting schedules starting in 2027, but shows no open-market buy or sell transactions.

How many restricted stock units does Shu Aimee hold in Ascendis Pharma (ASND)?

The filing lists RSU positions linked to 6,532, 3,197, and 9,552 underlying ordinary shares. Each restricted stock unit represents a contingent right to receive one American Depositary Share, and each ADS represents one ordinary share of Ascendis Pharma A/S.

When do Shu Aimee’s Ascendis Pharma (ASND) restricted stock units vest?

The RSUs begin vesting on March 1, 2027. One grant vests entirely on that date, while other grants vest in two or three equal annual installments starting on March 1, 2027, according to the detailed vesting footnotes in the disclosure.

Does Shu Aimee directly own Ascendis Pharma (ASND) ordinary shares in this Form 3?

The Form 3 shows zero directly held ordinary shares following the reported holdings. Instead, Shu Aimee’s disclosed equity exposure consists of multiple grants of restricted stock units that are settled in American Depositary Shares representing Ascendis Pharma ordinary shares.

Are there any buy or sell transactions in Shu Aimee’s Ascendis Pharma (ASND) Form 3?

No buy or sell transactions are reported in this Form 3. The entries are categorized as holdings, with unknown transaction codes, reflecting existing restricted stock unit awards rather than new open-market purchases or sales of Ascendis Pharma equity.

How are Ascendis Pharma (ASND) American Depositary Shares related to ordinary shares in this filing?

Each American Depositary Share represents one ordinary share of Ascendis Pharma. The footnotes explain that each restricted stock unit corresponds to a contingent right to receive one ADS, effectively tying each RSU to a single underlying ordinary share of the company.